project . 2020 - 2025 . On going

TheraLymph

Gene Therapy to restore lymphatic flow lymphedema
Open Access mandate for Publications and Research DataOpen Access mandate for ... European Commission
  • Funder: European CommissionProject code: 874708 Call for proposal: H2020-SC1-2019-Single-Stage-RTD
  • Funded under: H2020 | RIA Overall Budget: 8,064,950 EURFunder Contribution: 8,064,950 EUR
  • Status: On going
  • Start Date
    01 Jan 2020
    End Date
    30 Jun 2025
  • Detailed project information (CORDIS)
Description
Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that affects 4 millions people in Europe and more than 120 millions people worldwide. It is handicapping, painful and impacts substantially the quality of life. In western countries, lymphedema is generally a consequence of cancer treatments i.e. ten to fifteen percent of women will develop lymphedema after breast cancer. The main objective of Theralymph will be to establish a non-integrative gene therapy for this unmet medical need. The theralymph translational research program brings together bench scientists from 5 European c...
Description
Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that affects 4 millions people in Europe and more than 120 millions people worldwide. It is handicapping, painful and impacts substantially the quality of life. In western countries, lymphedema is generally a consequence of cancer treatments i.e. ten to fifteen percent of women will develop lymphedema after breast cancer. The main objective of Theralymph will be to establish a non-integrative gene therapy for this unmet medical need. The theralymph translational research program brings together bench scientists from 5 European c...
Any information missing or wrong?Report an Issue